Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

China SXT Pharmaceuticals (SXTC) Invested Capital: 2018-2025

Historic Invested Capital for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Sep 2025 value amounting to $20.3 million.

  • China SXT Pharmaceuticals' Invested Capital rose 34.03% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year increase of 34.03%. This contributed to the annual value of $15.5 million for FY2025, which is 10.60% up from last year.
  • China SXT Pharmaceuticals' Invested Capital amounted to $20.3 million in Q3 2025, which was up 30.71% from $15.5 million recorded in Q1 2025.
  • China SXT Pharmaceuticals' Invested Capital's 5-year high stood at $28.1 million during Q1 2021, with a 5-year trough of $5.2 million in Q3 2023.
  • Over the past 3 years, China SXT Pharmaceuticals' median Invested Capital value was $15.0 million (recorded in 2023), while the average stood at $14.2 million.
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 197.84% in 2021, then plummeted by 67.80% in 2023.
  • MRQ analysis of 5 years shows China SXT Pharmaceuticals' Invested Capital stood at $15.9 million in 2021, then increased by 1.17% to $16.1 million in 2022, then crashed by 67.80% to $5.2 million in 2023, then soared by 192.31% to $15.2 million in 2024, then soared by 34.03% to $20.3 million in 2025.
  • Its Invested Capital was $20.3 million in Q3 2025, compared to $15.5 million in Q1 2025 and $15.2 million in Q3 2024.